GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.

Renal cell carcinoma (RCC) by Prof. David Pfister, University Hospital of Cologne, Germany

 

After finishing medical school in November 2004 Dr Pfister started his residency in the Department of Urology at the University of Cologne. For his endoscopic training, he switched to the General Hospital in Weiden (Oberpfalz/Bavaria) between August 2006 and March 2007. After returning to Cologne Dr Pfister heightened my oncologic education under Prof. Heidenreich. The oncologic training consisted of two arms: medical and surgical oncology. In 2009 his education was augmented at the University Hospital of Aachen. In 2010 he passed his urologic board exam. Since 2011 Dr Pfister has been working as a staff urologist with main interests in castration-resistant prostate cancer and testicular cancer. In 2011 he passed the Charles Huggins grant, an educational grant at the Center for Prostate Disease Research in Maryland, USA. In 2012 Dr Pfister received an additional qualification in the systemic treatment of solid tumours and since that time he has organised and led the urological clinical trial centre. In 2012 Dr Pfister qualified as a Professor and became an Associate Professor in November 2012 for medical oncologic treatment in urological tumours. At the end of 2015 he became the Commissionary Leader of the Urologic Department of the University of Aachen. Since 2016 Dr Pfister has become the Deputy Director of the Department of Urology, Uro-oncology and Robot-Assisted Surgery, University Hospital of Cologne. Special interest is castration-resistant, radiation-resistant prostate cancer and testicular cancer.

Prof. David Pfister has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Merck, MSD, Janssen and Pfizer. 

Programme summary
Share this programme
Supporter Acknowledgement
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

podcast Podcast

Episode

of

episode
  • clock 19 MIN
  • calendar Jul 2024

this xxx bayer
conference-update Conference update
Oncology 
ASCO 2024 highlights

Experts
Prof. Shaheenah Dawood
Endorsed by
Bayer
  • download Downloadable
    Resources
  • clock 03 MIN
  • calendar Jul 2024

podcast Podcast
Hemostasis and bleeding disorders Oncology 
Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Experts
Prof. Dimitrios Tsakiris, Dr Lars Asmis
  • download Downloadable
    Resources
  • clock 14 MIN
  • calendar Sep 2023

Brought to you by COR2ED Medical Affairs in collaboration with Viatris.
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer

An interactive patient case video series from breast cancer specialists

Experts
Dr Elisa Agostinetto, Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology
publication Publication
Oncology  Patient Support
Surveillance and Diagnosis of HCC in Asia: Poster Presentation at ILCA 2023

Data from an Asia-Pacific patient and HCP survey

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Educational Grant from Roche.
video Video
Oncology 
Long-term Response in Advanced Colorectal Cancer

A video update from Prof. Gerald Prager

Experts
Assoc. Prof. Gerald Prager
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2023

Educational programme supported by an Independent Educational Grant from Bayer.